Terpenoid with anti-inflammatory activity as well as preparation method and application thereof

By extracting and isolating the terpene compound Limaxol D from slugs, the problem of failure to isolate anti-inflammatory active terpene components from slugs in the prior art was solved, and anti-inflammatory activity with a 47.11% NO generation inhibition rate was achieved. New inflammatory treatment options are provided with stability and economical benefits.

CN118908970AActive Publication Date: 2024-11-08GUANGXI INST OF BOTANY THE CHINESE ACAD OF SCI
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410925989.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-11
Publication Date
2024-11-08
Estimated Expiration
2044-07-11

AI Technical Summary

Technical Problem

The prior art has failed to isolate terpenes with anti-inflammatory activity from slugs, and new options for inflammation treatment are lacking.

Method used

A new terpene compound Limaxol D and its pharmaceutical salts or medicinal esterified derivatives were extracted and isolated from slugs, and prepared by reflux extraction, extraction and semi-preparation liquid chromatography and other steps of alkane compounds for preparation Anti-inflammatory drugs.

Benefits of technology

Limaxol D has a NO generation inhibitory rate of 47.11% in vitro pharmacological experiments, showing good anti-inflammatory activity, and the preparation method is simple and economical. The obtained ingredients are stable in nature and are suitable as a treatment drug for new inflammatory diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118908970A_ABST
    Figure CN118908970A_ABST
Patent Text Reader

Abstract

The invention relates to a terpenoid compound with anti-inflammatory activity and a preparation method and application thereof. The terpenoid comprises a compound as shown in a formula (I) or a medicinal salt or a medicinal esterified derivative as shown in the formula (I): # imgabs0 # (I). The novel terpenoid component with anti-inflammatory activity provided by the invention is separated from slugs for the first time; in-vitro pharmacological experiments prove that the NO generation inhibition rate is 47.11% when the concentration of the terpene component Limaxol D is 25 [mu] mol / L, and results show that the terpene component Limaxol D has good anti-inflammatory activity; therefore, the terpenoid component Limaxol D, or the derivative thereof, or the pharmaceutical salt thereof can be used for preparing anti-inflammatory drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to a terpene compound with anti-inflammatory activity and a preparation method and application thereof. Background Art

[0002] Terpenoids are compounds and their derivatives derived from mevalonic acid, whose molecular skeleton uses isoprene units (C5 units) as the basic structural units. They are widely present in nature and are the main components of the essences, resins, pigments, etc. of certain plants. They have multiple biological activities such as anti-inflammatory, antioxidant, antibacterial, antiviral, antitumor, liver protection, hypoglycemic, nervous system protection and cardiovascular system protection, and have little toxic and side effects. They are increasingly valued by natural medicine researchers and developers.

[0003] Slugs are molluscs with lungs, belonging to the Gastropoda class Slugidae. Because their bodies are covered with mucus, they resemble snails but have no shells, so they are also commonly known as "slugs" and "slugs". As a traditional Chinese medicine, "Shennong's Herbal Classic", "Compendium of Materia Medica", "Chinese Herbal Medicine Dictionary" and other medical history books record that "the taste is salty and cold, non-toxic. It can clear away heat and wind, detoxify edema, break blood stasis and promote menstruation, and treat stroke. Modern pharmacological research has shown that slugs have a significant inhibitory effect on cancer cells such as ascites sarcoma, Lewis tumor, and human non-small cell lung cancer. At the same time, they have a good effect on the treatment of chronic bronchitis and bronchial asthma. At present, there are certain research reports on chemical components, but there are no reports on the isolation of terpenoid components with anti-inflammatory activity from slugs.

[0004] In view of this, the present invention provides a terpene compound with anti-inflammatory activity and a preparation method and application thereof, which provides a new choice for inflammatory therapeutic drugs and makes up for the deficiencies of the prior art. Summary of the invention

[0005] The technical problem to be solved by the present invention is to provide a terpene compound with anti-inflammatory activity and a preparation method and application thereof.

[0006] The technical solution of the present invention to solve the above technical problems is as follows:

[0007] In the first aspect, a terpenoid compound having anti-inflammatory activity, wherein the terpenoid compound comprises a compound as represented by formula (I) or a pharmaceutically acceptable salt or pharmaceutically acceptable esterified derivative of formula (I):

[0008]

[0009] The compound or the pharmaceutically acceptable salt of formula (I) is selected from the salts formed by terpenoid compounds and organic or inorganic acids. The terpenoid compound with anti-inflammatory activity of the present invention is named Limaxol D.

[0010] The beneficial effects of the present invention are as follows: the new terpene component with anti-inflammatory activity provided by the present invention is separated from slugs for the first time; the terpene component Limaxol D is confirmed by in vitro pharmacological experiments to have a NO generation inhibition rate of 47.11% at a concentration of 25 μmol / L, and the results show that it has good anti-inflammatory activity; therefore, the terpene component Limaxol D or its pharmaceutically acceptable salts and esterified derivatives can be used in anti-inflammatory drugs.

[0011] Based on the above technical solution, the present invention can also be improved as follows.

[0012] In a second aspect, a terpenoid compound having anti-inflammatory activity is used to prepare an anti-inflammatory drug.

[0013] Furthermore, the terpenoid compound is used to prepare a drug for treating redness, swelling, heat, pain and / or functional disorders caused by inflammation caused by external irritants and / or injuries.

[0014] In a third aspect, a drug with anti-inflammatory activity comprises the terpenoid compound. A drug for treating inflammation of the present invention comprises an effective dose of an active ingredient selected from: a mixture of any one or more of the terpenoid compound with anti-inflammatory activity of the present invention, its pharmaceutically acceptable salt, and pharmaceutically acceptable esterified derivative.

[0015] Furthermore, it also includes pharmaceutically acceptable pharmaceutical excipients and / or carriers.

[0016] Furthermore, the dosage form of the drug is any one of granules, capsules, nanoformulations, controlled-release preparations, and sustained-release preparations.

[0017] In a fourth aspect, a preparation of a terpene compound having anti-inflammatory activity comprises the following steps:

[0018] (1) crushing the dried slugs, extracting with an alkane compound by refluxing, filtering and concentrating under reduced pressure to obtain a crude extract; flotating the crude extract with water and then extracting, concentrating the extract solution under reduced pressure to obtain an extract; dissolving the extract with methanol, precipitating crystals, and obtaining a crude crystalline sample;

[0019] (2) The crude crystal sample is prepared by semi-preparative liquid chromatography to obtain terpenoid compounds.

[0020] The beneficial effects of the above scheme are: the invention uses slugs as raw materials to extract and separate the potent anti-inflammatory active ingredients, the preparation method is simple, the operation is easy, and it has good potential economic benefits, and the obtained anti-inflammatory active ingredient Limaxol D is stable and easy to store. It is expected to be used as a compound or lead compound to develop new drugs for the treatment of inflammatory diseases.

[0021] Furthermore, in step (1), the ratio of the dried slug to the alkane compound used in each reflux extraction is (250-1000) g: (1-5) L; the alkane compound includes at least one of n-hexane, pentane, hexane, and petroleum ether;

[0022] In step (1), the extraction specifically comprises: extracting with ethyl acetate and flotating the crude extract with water for at least 4 times.

[0023] Furthermore, the semi-preparative liquid chromatograph in step (3) uses an eluent having a volume fraction ratio of n-hexane:ethyl acetate:isopropanol of 90:8:2 for isocratic elution to obtain an eluent with a retention time of 7.35 min, which is concentrated and dried to obtain terpenoid compounds.

[0024] Further, the slugs include at least one of the big slug (Limax maximus.), the yellow slug (L. flavus), the sheathed slug (Vaginulus alte), the wild slug (Agriolimax agrestis) and the two-line slime slug (Phiolomycus bilineatus). BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 It is the compound Limaxol D 1 H-NMR (500MHz, CD3OD) spectrum;

[0026] Figure 2 It is the compound Limaxol D 13 C-NMR (125MHz, CD3OD) spectrum;

[0027] Figure 3 is the HSQC spectrum of compound Limaxol D;

[0028] Figure 4 is the HMBC spectrum of compound Limaxol D;

[0029] Figure 5 It is the compound Limaxol D 1 H- 1 H COSY spectrum;

[0030] Figure 6 is the HR-EIMS spectrum of compound Limaxol D;

[0031] Figure 7 This is a graph showing the effect of the compound Limaxol D on the release of NO from macrophages. DETAILED DESCRIPTION

[0032] The principles and features of the present invention are described below, and the examples are only used to explain the present invention and are not used to limit the scope of the present invention. If no specific technology or conditions are specified in the embodiments, the technology or conditions described in the literature in this field or the product instructions are used. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased through regular channels.

[0033] Example 1

[0034] 1. Limaxol D is extracted, separated and purified from animal slugs

[0035] Animal giant slug (Limax maximus L.) was purchased from the medicinal material market, and the separation and purification process of extracting, separating and purifying terpenoid components from it was as follows:

[0036] (1) After 500 g of dried slugs were crushed, 2.5 L of n-hexane was refluxed and extracted three times, each time for 2 hours, and filtered. The filtrates were combined and concentrated under reduced pressure to obtain n-hexane extracts. The n-hexane extracts were floated with 0.1 L of water and extracted four times with ethyl acetate, 0.4 L of which were combined. The ethyl acetate extracts were concentrated under reduced pressure to obtain ethyl acetate extracts. The ethyl acetate extracts were heated and dissolved with 0.05 L of anhydrous methanol. After dissolution, they were cooled, allowed to stand, and crystals were precipitated. The crystals were filtered to obtain a crude crystalline sample. The crystalline sample was prepared by semi-preparative liquid phase to obtain Limaxol D.

[0037] (2) The crude crystal sample was dissolved in n-hexane and prepared by semi-preparative liquid chromatography (LC12 semi-preparative liquid chromatograph from Beijing Saipu Ruisi Technology Co., Ltd., HT-3501C semi-preparative liquid chromatograph from Suzhou Huitong Company) 18 A semi-preparative column (10 mm × 250 mm) was used, and a solution with a volume fraction ratio of 90:8:2 (n-hexane: ethyl acetate: isopropanol) was used for isocratic elution. The eluate with a retention time of 7.35 min was collected, and the eluate with a retention time of 7.35 min was concentrated and dried to obtain a compound shown in structural formula (I), which is the target terpenoid compound Limaxol D (63 mg).

[0038] 2. Identification of Limaxol D

[0039] Figure 1 It is the compound Limaxol D 1 H-NMR spectrum; Figure 2 It is the compound Limaxol D 13 C-NMR spectrum; Figure 3 is the HSQC spectrum of compound Limaxol D; Figure 4 is the HMBC spectrum of compound Limaxol D; Figure 5It is the compound LimaxolD 1 H- 1 H COSY spectrum; Figure 6 This is the HR-EIMS spectrum of the compound Limaxol D. Figure 6 ) shows that its quasi-molecular ion peak is [M+Na] + 631.3835 (calculated value 631.3817), indicating that the molecular formula is C 34 H 56 O9, unsaturation is 7. 1 H-NMR (500MHz, CD3OD), 13 C-NMR (125 MHz, CD3OD) data are shown in Table 1 below.

[0040] Table 1 NMR data of compound Limaxol D (in CD3OD)

[0041]

[0042] Based on the comprehensive analysis of the above spectral data, the compound structure was deduced as shown in formula (I), and was named Limaxol D:

[0043]

[0044] Example 2

[0045] 1. Activity detection

[0046] (1) Cell model: Mouse macrophage RAW264.7, obtained from Shanghai Cell Bank, Chinese Academy of Sciences. Complete culture medium: 90% DMEM medium + 10% fetal bovine serum + 1% P / S double antibody. Culture conditions: 37°C, 5% CO2, saturated humidity.

[0047] (2) Drugs and Reagents: The compounds used in the experiment were prepared from Example 1, accurately weighed, and dissolved in DMSO to a stock solution with a concentration of 20 μM for later use.

[0048] (3) CCK-8 method was used to determine cell viability. The steps are as follows:

[0049] The experimental groups were set as blank control group, background control group and compound group.

[0050] RAW264.7 cells in the logarithmic growth phase (purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences) were diluted to 2×10 5The single-cell suspension of cells / mL was inoculated into a 96-well plate (3 replicates per group) at a cell volume of 100 μL / well, and cultured in a CO2 incubator for 24 h. The plates were taken out and the test samples were added respectively. The blank control group was added with complete culture medium, the background group was added with only 100 μL complete culture medium without cells, and the compound group was added with different concentrations of the test compound (final concentration was 25 μM, 12.5 μM, and 6.25 μM), and the plates were placed in a CO2 incubator for further culture for 24 h. The plates were taken out and 10 μL of CCK-8 was added to each well. After incubation at 37°C for 1 h, the OD value of each well at a wavelength of 450 nm was detected by a microplate reader.

[0051] Calculation formula: Cell proliferation rate = (OD 样品 -OD 背景 ) / (OD 空白 -OD 背景 )×100%

[0052] (4) The Griess method was used to detect the effect of compounds on NO release from macrophages. The steps are as follows:

[0053] The experiment set up blank control group, DMSO group, model group, positive drug group (parthenolide) and compound group.

[0054] RAW264.7 cells in the logarithmic growth phase (purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences) were diluted to 2×10 5 A single cell suspension of cells / mL was inoculated into a 96-well plate (3 replicates per group) at a cell volume of 100 μL / well, and cultured in a cell culture incubator with a concentration of 5% CO2 and a temperature of 37°C for 24 hours. The plates were then taken out and complete culture medium was added to the blank control group and the model group, DMSO dilution was added to the DMSO group, and different concentrations of positive drugs and test compounds were added to the positive drug group and the compound group, respectively. After 1 hour of drug action, LPS (final concentration of 1 μg / mL) was used to induce a cell inflammation model in all experimental groups except the blank control group. After culturing in a CO2 incubator for 24 hours, the cell supernatant was collected, and the OD value at a wavelength of 540 nm was detected using an enzyme reader using the Griess method to detect the NO release and calculate the NO inhibition rate.

[0055] Calculation formula: Inhibition rate = [1-(OD 样品 -OD 空白 ) / (OD 模型 -OD 空白 )]×100%

[0056] 2. Activity Results

[0057] The results of cell viability assay showed that when the concentration of compound Limaxol D was below 25 μM (the compound could be completely dissolved only at a concentration below 25 μM), the cell proliferation rate was greater than 90%, indicating that compound Limaxol D had no obvious cytotoxic effect on RAW264.7 cells.

[0058] The results of NO release assay showed that Figure 7 As shown, when the concentration of compound Limaxol D is 25 μM, the inhibition rate of NO generation is 47.11% (the IC 50 The value was 0.90 μM), which showed that it had good anti-inflammatory activity.

[0059] In summary, the invention uses slugs as raw materials to extract and separate the potent anti-inflammatory ingredient Limaxol D, and the preparation method thereof is simple, has good potential economic benefits, and the obtained new anti-inflammatory ingredient Limaxol D is stable in nature and easy to store. It has good anti-inflammatory activity and is expected to be used as a lead compound to develop new inflammatory therapeutic drugs.

[0060] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. A terpene compound with anti-inflammatory activity, characterized in that: The terpenoid compounds include compounds represented by formula (I) or pharmaceutically acceptable salts or pharmaceutically acceptable esterified derivatives of formula (I):

2. An application of a terpenoid compound having anti-inflammatory activity, characterized in that: The terpenoid compound according to claim 1 is used for preparing anti-inflammatory drugs.

3. The use of a terpenoid compound with anti-inflammatory activity according to claim 2, characterized in that: The terpenoid compound is used for preparing medicine for treating redness, swelling, heat, pain and / or functional disorder caused by inflammation caused by external irritants and / or injuries.

4. A drug having anti-inflammatory activity, characterized in that The invention comprises the terpenoid compound as claimed in claim 1.

5. A drug with anti-inflammatory activity according to claim 4, characterized in that: Also included are pharmaceutically acceptable excipients and / or carriers.

6. A drug with anti-inflammatory activity according to claim 4, characterized in that: The dosage form of the medicine is any one of granules, capsules, nano preparations, controlled release preparations and sustained release preparations.

7. The preparation of a terpenoid compound with anti-inflammatory activity according to claim 1, characterized in that: The steps include: (1) crushing the dried slugs, extracting with an alkane compound by refluxing, filtering and concentrating under reduced pressure to obtain a crude extract; flotating the crude extract with water and then extracting, concentrating the extract solution under reduced pressure to obtain an extract; dissolving the extract with methanol, precipitating crystals, and obtaining a crude crystalline sample; (2) The crude crystal sample is prepared by semi-preparative liquid chromatography to obtain terpenoid compounds.

8. The preparation of a terpenoid compound with anti-inflammatory activity according to claim 7, characterized in that: In step (1), the ratio of the dried slug to the alkane compound used in each reflux extraction is (250-1000) g: (1-5) L; the alkane compound comprises at least one of n-hexane, pentane, hexane, and petroleum ether; In step (1), the extraction specifically comprises: extracting with ethyl acetate and flotating the crude extract with water for at least 4 times.

9. The preparation of a terpenoid compound with anti-inflammatory activity according to claim 7, characterized in that: The semi-preparative liquid chromatograph in step (3) uses an eluent having a volume fraction ratio of n-hexane:ethyl acetate:isopropanol of 90:8:2 for isocratic elution to obtain an eluent having a retention time of 7.35 min, which is concentrated and dried to obtain terpenoid compounds.

10. The preparation of a terpenoid compound with anti-inflammatory activity according to claim 7, characterized in that: The slugs include at least one of a big slug, a yellow slug, a sheathed foot slug, a wild slug and a two-line slime slug.

Citation Information

Patent Citations

  • Novel compound and preparation method thereof

    CN107868092A

  • Novel compound and preparation method and application thereof

    CN111269241A